Evamist

Evamist is a brand name of estradiol, approved by the FDA in the following formulation(s):

EVAMIST (estradiol - spray; transdermal)

• 
  Manufacturer: KV PHARM
  
  Approval date: July 27, 2007
  
  Strength(s): 1.53MG/SPRAY ^[RLD]

Has a generic version of Evamist been approved?

No. There is currently no therapeutically equivalent version of Evamist available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Evamist. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Dermal penetration enhancers and drug delivery systems involving same
  Patent 6,299,900
  Issued: October 9, 2001
  Inventor(s): Reed; Barry Leonard & Morgan; Timothy Matthias & Finnin; Barrie Charles
  Assignee(s): Monash University
  A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterized in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
  
  Patent expiration dates:
  
  
  • February 19, 2017
    
    ✓ 
    Patent use: MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE)
    ✓ 
    Drug product
  
  
  
  • February 19, 2017
    
    ✓ 
    Patent use: FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
    ✓ 
    Drug product
  
  



• 
  Dermal penetration enhancers and drug delivery systems involving same
  Patent 6,818,226
  Issued: November 16, 2004
  Inventor(s): Barry Leonard; Reed & Timothy Matthias; Morgan & Barrie Charles; Finnin
  Assignee(s): ACRUX DDS Pty. Ltd.
  A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterised in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
  
  Patent expiration dates:
  
  
  • February 19, 2017
    
    ✓ 
    Patent use: FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
    ✓ 
    Drug product
  
  
  
  • February 19, 2017
    
    ✓ 
    Patent use: MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE)
    ✓ 
    Drug product
  
  



• 
  Transdermal delivery of hormones
  Patent 6,923,983
  Issued: August 2, 2005
  Inventor(s): Morgan; Timothy Matthias & Bakalova; Margarita Vladislavova & Klose; Karthryn Traci-Jane & Finnin; Barrie Charles & Reed; Barry Leonard
  Assignee(s): Acrux DDS PTY LTD
  The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone to an animal which comprises applying an effective amount of the hormone in the form of the drug delivery system of the present invention
  
  Patent expiration dates:
  
  
  • February 19, 2017
    
    ✓ 
    Patent use: MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE)
    ✓ 
    Drug product
  
  
  
  • February 19, 2017
    
    ✓ 
    Patent use: FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
    ✓ 
    Drug product
  
  



• 
  Dispensing device
  Patent 6,978,945
  Issued: December 27, 2005
  Inventor(s): Wong; Kon Euan & Bayly; Mark Simon
  Assignee(s): Acrux DDS Pty Ltd
  Hand-held dispensing devices for dispensing and applying a substance to the skin of a host are described. The devices include a hollow body, a capsule mounted within the hollow body for containing the substance, a nozzle mounted within the hollow body communicating with the substance in the capsule, an actuator to cause metered quantities of the substance to be dispensed from the capsule through the nozzle, a shroud defining an exit space for receiving the substance emerging from the nozzle, and a cap detachably mounted on the shroud to selectively open and close the nozzle and thereby control escape of the substance from the capsule.
  
  Patent expiration dates:
  
  
  • November 30, 2021
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 27, 2010 - NEW DOSAGE FORM
  
  

See also...

• Evamist Consumer Information (Drugs.com)
• Evamist Spray Consumer Information (Wolters Kluwer)
• Evamist for use on skin Consumer Information (Cerner Multum)
• Estradiol Consumer Information (Drugs.com)
• Estradiol Consumer Information (Wolters Kluwer)
• Estradiol Acetate Consumer Information (Wolters Kluwer)
• Estradiol Cypionate Consumer Information (Wolters Kluwer)
• Estradiol Gel Consumer Information (Wolters Kluwer)
• Estradiol Gel Packets Consumer Information (Wolters Kluwer)
• Estradiol Patch Consumer Information (Wolters Kluwer)
• Estradiol Ring Consumer Information (Wolters Kluwer)
• Estradiol Spray Consumer Information (Wolters Kluwer)
• Estradiol Valerate Consumer Information (Wolters Kluwer)
• Estradiol Weekly Patch Consumer Information (Wolters Kluwer)
• Estring Ring Consumer Information (Wolters Kluwer)
• Estradiol injection Consumer Information (Cerner Multum)
• Estradiol oral Consumer Information (Cerner Multum)
• Estradiol topical for use on skin Consumer Information (Cerner Multum)
• Estradiol transdermal Consumer Information (Cerner Multum)
• Estradiol vaginal Consumer Information (Cerner Multum)
• Estradiol AHFS DI Monographs (ASHP)